AndroGel

ApprovedSmall molecule

RRepros Therapeutics Inc.

AndroGel is one of 199 small molecule programs targeting Hypogonadism. It is currently in Approved.

Indications

Total Trials

Active Trials

198

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypogonadismActive, not recruiting

Hypogonadotropic HypogonadismActive, not recruiting

LymphomaActive, not recruiting

Brain InjuryActive, not recruiting

Prostate CancerActive, not recruiting

Type 2 DiabetesActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

HypogonadismApproved

Active, not recruiting

Hypogonadotropic HypogonadismPhase 3

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Brain InjuryApproved

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Sickle Cell DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

AndroGel

RRepros Therapeutics Inc.

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Norvir

AbbVie

Preclinical

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Critically Ill

NCT05825092

Clinical

Trials by Indication[1]

Hypogonadism5 trials

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Completed·RRepros Therapeutics Inc.·Phase 3·NCT00962637·194 enrolled

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Completed· AbbVie logo

AbbVie·Phase 4·NCT04274894·246 enrolled

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Completed·UUniversity at Buffalo·Phase 4·NCT00350701·49 enrolled

Show 2 more trials

Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.

Unknown status·FFBM Industria Brasileira Ltda·Phase 3·NCT03281187·228 enrolled

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

Terminated·UUniversity at Buffalo·N/A·NCT00467987·47 enrolled

Testosterone4 trials

The Testosterone Trials in Older Men

Completed·UUniversity of Pennsylvania·Phase 3·NCT00799617·790 enrolled

Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.

Completed·NNational Institute on Aging (NIA)·Phase 2·NCT00104572·44 enrolled

Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR

Completed·LLamm, Steven, M.D.··NCT00425568·30 enrolled

Show 1 more trial

Testosterone & Tamoxifen Trial

Terminated·UUniversity Medical Center Groningen·N/A·NCT05156606·5 enrolled

Hypogonadotropic Hypogonadism2 trials

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Completed·RRepros Therapeutics Inc.·Phase 3·NCT01993212·120 enrolled

Completed·RRepros Therapeutics Inc.·Phase 3·NCT01993225·120 enrolled

Pain Perception1 trial

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception

Completed·—·Phase 2·NCT00351819·84 enrolled

Lymphoma1 trial

Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality

Completed·LLars Møller Pedersen·Phase 2·NCT04492553·7 enrolled

9 more indications

Prostate Cancer1 trial

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Terminated·UUniversity of Chicago·Phase 2·NCT00515112·6 enrolled

Testosterone Replacement Therapy1 trial

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Completed· AbbVie logo

AbbVie·Phase 4·NCT03518034·5,246 enrolled

Critically Ill1 trial

Effects of Early Testosterone Gel Administration on Physical Performance in the Critically Ill

Recruiting·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT05825092·600 enrolled

Brain Injury1 trial

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

Completed·—·Phase 4·NCT01201863·46 enrolled

Testicular Cancer1 trial

Short-term Testosterone Replacement in Testicular Cancer Survivors

Completed·UUniversity Medical Center Groningen·Phase 2·NCT03339635·32 enrolled

Sickle Cell Disease1 trial

Androgen Regulation of Priapism in Sickle Cell Disease

Withdrawn·JJohns Hopkins University·Phase 1·NCT01940718

Type 2 Diabetes1 trial

Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

Completed·SSolvay Pharmaceuticals·Phase 2·NCT00141492

Alzheimer's Disease1 trial

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

Completed·MMichael E. DeBakey VA Medical Center·N/A·NCT00392912·10 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

Completed·MMarius Pharmaceuticals·Phase 3·NCT03198728·314 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for AndroGel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AndroGel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AndroGel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Repros Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: RRepros Therapeutics Inc.

AndroGel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hypogonadism5 trials

Testosterone4 trials

Hypogonadotropic Hypogonadism2 trials

Pain Perception1 trial

Lymphoma1 trial

Prostate Cancer1 trial

Testosterone Replacement Therapy1 trial

Critically Ill1 trial

Brain Injury1 trial

Testicular Cancer1 trial

Sickle Cell Disease1 trial

Type 2 Diabetes1 trial

Alzheimer's Disease1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News